GeneDx Hldgs Analyst Ratings
Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $54
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating
GeneDx Holdings Initiated at Equal-Weight by Wells Fargo
Craig-Hallum Issues a Buy Rating on GeneDx Holdings (WGS)
GeneDx Holdings Price Target Raised to $45.00/Share From $35.00 by BTIG
GeneDx Hldgs Analyst Ratings
Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $32
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $46
Craig-Hallum Remains a Buy on GeneDx Holdings (WGS)
BTIG Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $45
TD Cowen Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $50
Buy Rating Affirmed: GeneDx Holdings' Financial Growth and Promising Outlook Propel Stock's Upward Trajectory
GeneDx Hldgs Analyst Ratings
Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $28
GeneDx Hldgs Analyst Ratings
GeneDx Hldgs Analyst Ratings
TD Cowen Adjusts GeneDx Holdings' Price Target to $24 From $14, Keeps Buy Rating
TD Cowen: Maintains GeneDx Hldgs (WGS.US) rating, adjusted from buy to buy rating, and adjusted target price from $14.00 to $24.00.